Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lithium and synaptic plasticity.

P C Salinas1, A C Hall

  • 1Developmental Biology Research Centre, The Randall Institute, King's College London, UK. patricia.salinas@kcl.ac.uk

Bipolar Disorders
|March 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A potential key role for alpha-haemolysin of <i>Staphylococcus aureus</i> in mediating chondrocyte death in septic arthritis.

Bone & joint research·2018
Same author

A novel organ culture model of a joint for the evaluation of static and dynamic load on articular cartilage.

Bone & joint research·2018
Same author

Iatrogenic articular cartilage injury: the elephant in the operating theatre: the surgeons' role in chondroprotection.

The bone & joint journal·2017
Same author

Drying of open animal joints in vivo subsequently causes cartilage degeneration.

Bone & joint research·2016
Same author

Hyperosmolarity normalises serum-induced changes to chondrocyte properties in a model of cartilage injury.

European cells & materials·2016
Same author

Impact of bread making on fructan chain integrity and effect of fructan enriched breads on breath hydrogen, satiety, energy intake, PYY and ghrelin.

Food & function·2015
Same journal

Epigenetic Age Accelerations and the Clinical Presentation of Bipolar Disorders: A Latent Profile Analysis in the FACE-BD Sample.

Bipolar disorders·2026
Same journal

Risk of Major Malformations Following First-Trimester Exposure to Cariprazine: Preliminary Data From the MGH National Pregnancy Registry for Psychiatric Medications.

Bipolar disorders·2026
Same journal

The Theory of Metabolic Jet Lag in Bipolar Disorder: A Pilot Feasibility Study Exploring the Association Between Eating Rhythm Disruption and Illness Burden Parameters.

Bipolar disorders·2026
Same journal

A 3-Month Follow-Up Pilot Study on Accelerated Intermittent Theta Burst Stimulation for Bipolar Depression.

Bipolar disorders·2026
Same journal

Biofluid Biomarkers of Cognitive Functioning in Bipolar Disorder: A Systematic Review by the Targeting Cognition and Older-Age Bipolar Disorder ISBD Task Forces.

Bipolar disorders·2026
Same journal

Enhancing Affective Cognitive Control in Bipolar Disorder Using Transcranial Alternating Current Stimulation: A Double-Blind, Randomized, Sham-Controlled Clinical Trial and Proof of Concept Study.

Bipolar disorders·2026
See all related articles

Lithium

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Lithium has been a cornerstone treatment for bipolar disorder since the 1950s.
  • Its primary mechanism was thought to be inositol depletion affecting neuronal signaling.
  • Emerging evidence suggests alternative pathways are involved.

Purpose of the Study:

  • To explore the non-inositol depletion mechanisms of lithium's action.
  • To investigate the role of glycogen synthase kinase-3 beta (GSK-3beta) inhibition.

Main Methods:

  • Review of recent findings on lithium's molecular targets.
  • Analysis of studies investigating GSK-3beta activity and its downstream effects.

Main Results:

  • Lithium directly inhibits glycogen synthase kinase-3 beta (GSK-3beta) non-competitively.

Related Experiment Videos

  • GSK-3beta inhibition influences neuronal plasticity, axonal remodeling, and synaptic protein levels.

    • Conclusions:

    • Lithium's therapeutic effects may be partly mediated by GSK-3beta inhibition.
    • Targeting GSK-3beta offers potential for novel bipolar disorder treatments.